Tirzepatide postpartum claims: what the science actually says

What did @lucianatorquati actually say?

Honestly? It's hard to tell. The transcript provided appears to be a badly garbled auto-translation of a Spanish-language video, likely about tirzepatide (branded as Mounjaro or Zepbound), given the hashtags #tirzepatide and #posparto. The creator says they're clearing up "frequent doubts" about "La Tirze" alongside their doctor. Beyond that, the transcript devolves into incoherent machine-translated fragments. Direct quotes like "I'm also a presio?" and "Blood of the Vetamino" suggest the auto-captions failed catastrophically on Spanish audio. What we can reasonably infer from context is that this video is a GLP-1 explainer aimed at a Spanish-speaking audience, possibly addressing tirzepatide use in a postpartum context. We cannot responsibly fact-check specific claims when we cannot confirm what was actually said with confidence.

Does the science back tirzepatide use in postpartum patients?

The short answer: the evidence for tirzepatide in postpartum women is thin, and the safety concerns are real enough to warrant serious caution. Tirzepatide is not currently approved for postpartum use, and its safety during breastfeeding has not been established in humans.

Tirzepatide works as a dual GIP and GLP-1 receptor agonist. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) demonstrated 20.9% mean body weight reduction at the highest dose in adults with obesity, which is why interest in the drug has exploded. But that trial excluded breastfeeding women entirely. Animal studies show tirzepatide is present in rat milk (FDA prescribing information, Eli Lilly, 2023), and given that GLP-1 receptor agonists affect appetite signaling, the theoretical risk to a nursing infant is not something to dismiss. The Endocrine Society does not currently recommend GLP-1 or GIP/GLP-1 agonists during lactation. Postpartum patients are already navigating significant hormonal shifts, and introducing a drug that causes nausea, vomiting, and caloric restriction in that window carries risks for both infant nutrition and maternal recovery that simply haven't been studied adequately.

What did they get wrong (or right)?

We cannot confirm specific errors without a legible transcript. That is itself a problem worth naming: health content at nearly 50,000 views, covering a prescription medication in a postpartum context, should not require viewers to decode garbled auto-captions to understand what's being claimed. What we can say is that the framing, a creator and their personal doctor answering "frequent doubts" about tirzepatide for a postpartum audience, raises legitimate concerns regardless of the specific words used.

• Tirzepatide requires a valid prescription and individualized clinical evaluation. A TikTok Q&A format is not a substitute for that.
• If the video addressed weight loss postpartum without explicitly flagging breastfeeding contraindications, that would be a meaningful omission.
• If it normalized compounded tirzepatide as equivalent to brand-name Zepbound or Mounjaro, that would be inaccurate. The FDA has specifically warned that compounded versions are not the same product and carry additional quality risks (FDA Drug Shortages guidance, 2023).

What should you actually know about tirzepatide and the postpartum period?

Postpartum weight retention is a legitimate medical concern, and interest in GLP-1 class drugs is understandable. But the postpartum window is not the time to experiment with medications lacking safety data for that population. Here is what the current evidence actually supports.

• Tirzepatide is FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management in adults with obesity or overweight plus a weight-related condition (Zepbound). Neither label covers postpartum use specifically.
• Breastfeeding women were excluded from major tirzepatide trials. No human lactation data exists. Clinical guidance defaults to avoiding the drug during breastfeeding (LactMed, NIH, updated 2024).
• Any postpartum patient considering tirzepatide should have a thorough conversation with an OB-GYN or endocrinologist, not a social media video, before starting.
• The drug does produce significant weight loss in studied populations, but side effects including severe nausea, vomiting, and gastroparesis-like symptoms can interfere with postpartum recovery and nutritional needs.